FDA

Showing 15 posts of 1442 posts found.

FDA sign

FDA criticised for safety data flaws

January 18, 2016
Sales and Marketing FDA, US Government Accountability Office, pharmacovigilance, post-marketing data, safety

The US FDA is failing to meet its ‘statutorily required’ obligations to track safety data for drugs post-marketing and publish …

FDA

FDA says no to BioMarin’s Duchenne Muscular Dystrophy drug

January 14, 2016
Medical Communications, Sales and Marketing BioMarin, Duchenne Muscular Dystrophy, FDA, Kyndrisa, drisapersen

The FDA has rejected BioMarin’s Duchenne Muscular Dystrophy (DMD) drug Kyndrisa, saying there was not enough evidence that the drug …

dr_robert_califf_image_via_duke_university_school_of_medicine

Senate panel approves Dr Robert Califf as FDA commissioner

January 13, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Dr Robert Califf, FDA, FDA commissioner, Senate

A senate panel has approved president Obama’s nominee Dr Robert Califf to lead the FDA by a clear majority, although …

FDA sign

FDA review for Sanofi and Regeneron’s biologic arthritis drug

January 8, 2016
Medical Communications, Sales and Marketing FDA, Regeneron, Sanofi, biologics, rheumatoid arthritis, sarilumab

The FDA has accepted for review a Biologics License Application (BLA) from Sanofi and Regeneron for the rheumatoid arthritis treatment …

2000px-food_and_drug_administration_logo

FDA approves AstraZeneca’s gout drug Zurampic

December 23, 2015
Sales and Marketing AstraZeneca, FDA, Zurampic, gout, lensinurad

The US FDA has approved AstraZeneca’s Zurampic to treat high levels of uric acid in the blood. The drug is …

Actelion building

Actelion ready to launch Uptravi after FDA approval

December 22, 2015
Research and Development, Sales and Marketing Actelion, FDA, Jean-Paul Clozel, Uptravi, pulmonary arterial hypertension, selexipag

Actelion says it is ready to launch Uptravi, its drug for pulmonary arterial hypertension in the US in January, after …

Gilenya

EMA adds warning label to Novartis’ MS treatment Gilenya

December 22, 2015
Manufacturing and Production EMA, European Medicines Agency, FDA, Novartis, PML, basal cell carcinoma, fingolimod, gilenya

Drug safety regulators in Europe have said they will add warnings to the label and prescribing information of Gilenya (fingolimod), …

Sun Pharma logo

Sun Pharma hit by FDA inspection warning

December 22, 2015
Manufacturing and Production FDA, Sun Pharma, manufacturing, production

Sun Pharma shares fell some 7% early this week after it emerged the Indian company received a warning letter from …

Chest x ray

Roche lung cancer drug Alecensa gets rapid US approval

December 14, 2015
Sales and Marketing Alecensa, FDA, Genentech, Roche, accelerated approval, alectinib, lung cancer, non-small cell lung cancer

The US health watchdog has approved Alecensa, a drug for people with certain types of non-small cell lung cancer manufactured …

Novolog pen

Novo Nordisk files for new insulin approval

December 10, 2015
Manufacturing and Production, Research and Development, Sales and Marketing FDA, NDA, Novo Nordisk, NovoLog, diabetes, insulin aspart, new drug application

Novo Nordisk has submitted a New Drug Application (NDA) for faster-acting insulin aspart to the FDA. If successful, the Danish …

Logos

New regulatory submissions for AbbVie and Novo Nordisk

December 4, 2015
Medical Communications AbbVie, EMA, FDA, Novo Nordisk, Viekira Pak, insulin aspart

AbbVie and Novo Nordisk have submitted new drug applications to the US FDA and European Medicines Agency (EMA) respectively. The …

Empliciti logo

FDA approves BMS and AbbVie’s Empliciti for multiple myeloma

December 1, 2015
Manufacturing and Production, Sales and Marketing AbbVie, BMS, Bristol-Myers Squibb, Empliciti, FDA, elotuzumab, multiple myeloma

The US healthcare regulator has approved Empliciti – a multiple myeloma treatment co-developed by Bristol-Myers Squibb and AbbVie. The FDA …

dna

Companies face mixed fortunes in ultra-orphan approvals

November 26, 2015
Medical Communications, Research and Development BioMarin, Duchenne Muscular Dystrophy, FDA, Genzyme, NICE, ultra-orphan drugs

UK regulator NICE has recommended Vimizin, a drug for a very rare genetic disorder, after the manufacturer and NHS England …

Beximco logo

FDA approves Beximco to manufacture Carvedilol for US

November 24, 2015
Manufacturing and Production Bangladesh, Beximco, Carvediol, FDA, exports, generics

Beximco Pharmaceuticals has become the first Bangladeshi pharma company to receive approval for a prescription drug to be manufactured in …

US Capitol building

Obama FDA commissioner nominee Califf defends big pharma ties

November 18, 2015
Sales and Marketing Bernie Sanders, FDA, FDA commissioner, Robert Califf

President Obama’s nominee to head the FDA was forced to defend his history of ties to the pharma industry as …

The Gateway to Local Adoption Series

Latest content